arrow
S

Sayda M. Elbashir

alnylam pharmaceuticals
H指数:29
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus

mRNA-1345前融合F糖蛋白编码mRNA疫苗的设计与临床前评估:针对呼吸道合胞病毒

Vaccine
IF3.5
2025-08-200
OA
Inclusion of a retroviral protease enhances the immunogenicity of VLP-forming mRNA vaccines against HIV-1 or SARS-CoV-2 in mice

将逆转录病毒蛋白酶包含在内可增强小鼠中针对HIV-1或SARS-CoV-2的VLP形成mRNA疫苗的免疫原性

2025-04-300
PRE
mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice

mRNA-1273疫苗针对JN.1或KP.2的变体能够诱导小鼠产生对SARS-CoV-2 JN.1亚系的交叉中和反应。

VACCINE
IF3.5
2025-04-010
OAAI
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection
2024-11-060
PRE
Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2
2023-09-137
PRE
Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice

改变mRNA-1273给药间隔会影响小鼠免疫反应的动力学,质量和大小

2022-11-085
OAAI
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
2022-10-20117
OA
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

接种疫苗的人和小鼠对SARS-CoV-2变异的不同敏感性

2022-08-0110
OAAI
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
MED
IF11.8
2022-05-016
OAAI
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
2022-02-0252
OAAI
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
2021-12-09109
OA
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
2021-08-2041
OAAI